244 results on '"Shumel, Brad"'
Search Results
2. Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis
3. Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis’
4. Integrated Exposure–Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population Analysis
5. Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study
6. Dupilumab Treatment Reduces Hospitalizations in Adults With Moderate-to-Severe Atopic Dermatitis
7. Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment
8. Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks
9. Examining the Role of Type 2 Inflammation in Eosinophilic Esophagitis
10. Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis
11. Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older
12. A case series of live attenuated vaccine administration in dupilumab‐treated children with atopic dermatitis
13. 564 - Conjunctivitis adverse events in dupilumab clinical trials
14. Dupilumab Improves Treatment Satisfaction and Health-Related Quality of Life in Adults with Atopic Dermatitis in Clinical Practice: Subgroup Analysis of Black/African American Population from RELIEVE-AD
15. Dupilumab Improves Disease Control and Patient-Reported Outcomes in Adults with Atopic Dermatitis in Clinical Practice: Subgroup Analysis of Black/African American Population from RELIEVE-AD
16. Dupilumab Decreases Concomitant Therapy use in Adults with Atopic Dermatitis in Clinical Practice: Subgroup Analysis of Black/African American Population from RELIEVE-AD
17. Laboratory Safety of Dupilumab in Patients Aged 6–11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial
18. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
19. Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial
20. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
21. Patient-Reported Ocular Disorders and Symptoms in Adults with Moderate-to-Severe Atopic Dermatitis: Screening and Baseline Survey Data from a Clinical Trial
22. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
23. Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials
24. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
25. Efficacy of dupilumab in moderate and severe atopic dermatitis
26. 329 Efficacy and safety of dupilumab treatment with concomitant topical corticosteroids in children aged 6 months to 5 years with severe atopic dermatitis
27. 342 A case series of live attenuated vaccine administration in dupilumab-treated children with atopic dermatitis
28. Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis
29. 687 - Treatment of conjunctivitis in dupilumab-treated patients with atopic dermatitis: an observational study.
30. 682 - Dupilumab demonstrates higher likelihood of maintaining efficacy outcomes compared with lebrikizumab in monotherapy at week 52: results from a placebo-adjusted indirect comparison analysis.
31. 675 - Dupilumab demonstrates higher likelihood of achieving improvements in signs, symptoms, and quality of life vs lebrikizumab: results from a placebo-adjusted indirect comparison analysis.
32. 33322 Dupilumab improves patient-reported outcomes among adults with moderate-to-severe atopic dermatitis (AD) in clinical practice: 30-36 month results from the RELIEVE-AD study
33. 34021 Family impact of moderate-to-severe atopic dermatitis in children aged <12 years: Results from 732 patients in the PEDIatric STudy in Atopic Dermatitis (PEDISTAD) observational study
34. 33325 Long-term dupilumab effectiveness on health-related quality of life (HRQoL) and work productivity in atopic dermatitis (AD): Results from RELIEVE-AD
35. Disease Burden and Unmet Need in Eosinophilic Esophagitis
36. Dupilumab Reduces Biomarkers of Type 2 Inflammation in Adult and Adolescent Patients With Eosinophilic Esophagitis: Results From Parts A and C of a Three-Part, Phase 3 LIBERTY EoE TREET Study
37. Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment
38. Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks
39. Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
40. Inhibition of Angiopoietin-Like Protein 3 With Evinacumab in Subjects With High and Severe Hypertriglyceridemia
41. Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents
42. 52842 Dupilumab Improves Health-Related Quality of Life and Work Productivity Among Adults With Moderate-to-Severe Atopic Dermatitis in Clinical Practice: 4-Year Follow-up Results From the RELIEVE-AD Study.
43. 27375 Dupilumab provides early and sustained improvement of sleep disturbance in children ≥ 6 years with severe atopic dermatitis (AD) and adolescents with moderate-to-severe AD
44. 27406 Dupilumab improves signs and symptoms of severe atopic dermatitis in children aged 6–11 years with and without comorbid asthma
45. 27394 Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs, symptoms, and quality of life in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial
46. 26839 Dupilumab with topical corticosteroids results in rapid and sustained improvement in adults with moderate-to-severe atopic dermatitis across all anatomic regions over 52 weeks
47. 27350 Dupilumab improves Eczema Area and Severity Index regional scores across all anatomical regions in children aged 6–11 years with severe atopic dermatitis (AD)
48. 27424 Infections in adults with moderate-to-severe atopic dermatitis treated with dupilumab: long-term data from an open-label extension (OLE) study
49. The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis
50. Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.